CP60 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent top-line expansion indicates continued demand across Cooper’s medical instruments and supplies portfolio. Sustained revenue growth provides a platform for operating leverage, supports investment in innovation and commercial coverage, and strengthens the company’s ability to defend or expand market share.
Conservative Balance SheetManageable leverage and growing equity give Cooper financial flexibility to fund product development, commercial expansion and strategic initiatives without relying heavily on additional borrowing. This conservative balance-sheet position also improves resilience when profitability or cash conversion temporarily weakens.
Fertility Innovation And Market ShareBroad-based fertility growth and ongoing product launches support a durable position in a market management identifies as benefiting from delayed family formation, greater treatment access and rising utilization. Clinic wins and innovation can deepen customer relationships and sustain expansion over multiple periods.
Bears Say
Weak Cash ConversionThe sharp TTM deterioration in operating and free cash flow weakens earnings quality and reduces internally generated funding for investment and capital returns. Operating cash flow covered only about 51% of net income, leaving future results more exposed to working-capital swings or elevated spending.
Operating Margin CompressionSubstantial operating-margin contraction shows that revenue growth is not currently translating efficiently into operating profit. If higher costs, commercial investment or other pressures persist, weaker margins could limit earnings growth, reduce cash generation and constrain the returns available from future expansion.
Super-Premium Product GapLack of coverage in a growing, higher-revenue segment leaves CooperVision without a complete offering where customer demand and monetization appear attractive. Closing this gap requires successful premium product development and adoption, while competitors may capture patient spending and strengthen their category positions.
Cooper Co News
CP60 FAQ
What was Cooper Co’s price range in the past 12 months?
Currently, no data Available
What is Cooper Co’s market cap?
Cooper Co’s market cap is CHF9.01B.
When is Cooper Co’s upcoming earnings report date?
Cooper Co’s upcoming earnings report date is Dec 03, 2026 which is in 62 days.
How were Cooper Co’s earnings last quarter?
Cooper Co released its earnings results on Sep 09, 2026. The company reported CHF0.962 earnings per share for the quarter, beating the consensus estimate of CHF0.94 by CHF0.022.
Is Cooper Co overvalued?
According to Wall Street analysts Cooper Co’s price is currently Undervalued.
Does Cooper Co pay dividends?
Cooper Co does not currently pay dividends.
What is Cooper Co’s EPS estimate?
Cooper Co’s EPS estimate is 0.9.
How many shares outstanding does Cooper Co have?
Currently, no data Available
What happened to Cooper Co’s price movement after its last earnings report?
Cooper Co reported an EPS of CHF0.962 in its last earnings report, beating expectations of CHF0.94. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cooper Co?
Currently, no hedge funds are holding shares in CH:CP60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cooper Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF54.59 (― Upside)
CHF54.59 (― Upside)
Blogger Sentiment
Neutral
CH:CP60 Sentiment 50%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth CHF453.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cooper Co
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
CP60 Company Deck
CP60 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: the company delivered an earnings beat, record quarterly free cash flow, an 86% year-to-date free cash flow increase, a favorable tax resolution, substantial share repurchases and continued fertility and product momentum. These strengths were tempered by flat CooperVision revenue, U.S. channel destocking that will continue into Q4, legacy hydrogel declines, China and Asia Pacific challenges, near-term margin pressure and a higher expected fiscal 2027 tax rate. Management expressed confidence that inventory actions will be completed in Q4 and that increased commercial investment will support improved growth.View all CH:CP60 earnings summariesCP60 Net sales Breakdown
67.05% CooperVision
32.95% CooperSurgical
CP60 Stock 12 Month Forecast
Average Price Target
―Baxter International
―
Merit Medical Systems
―
Staar Surgical
―
Teleflex
―
Bausch + Lomb Corporation
―